Dr. Whitcup is founder and Chief Executive Officer of Akrivista and Whitecap Biosciences, two companies focused on the development and commercialization of novel therapies in ophthalmology and dermatology. Dr. Whitcup has published more than 250 scientific articles and co-authored a leading textbook on uveitis and ocular immunology. Dr. Whitcup currently serves on the boards of Menlo Therapeutics, Scilex Holding Company and Anivive. He previously served on the boards of Nightstar Therapeutics and Avanir Pharmaceuticals. Dr. Whitcup holds a B.A. in Neurobiology and Behavior from Cornell University and an M.D. from Cornell University Medical College. Dr. Whitcup has completed a residency in Internal Medicine at UCLA, a residency in Ophthalmology at Harvard Medical School-Massachusetts Eye & Ear Infirmary and a fellowship in Uveitis and Ocular Immunology at the National Eye Institute, National Institutes of Health. He is a Diplomate of both the American Board of Institute, David Geffen School of Medicine at the University of California at Los Angeles.